Cryosite Limited · ASX:CTE
Cryosite — Investor Presentation (May 2024)
23 slides from Cryosite's investor presentation, May 9, 2024
Slide 1: Corporate Presentation
Corporate Presentation May 2024
Slide 2: Disclaimer
Disclaimer The following disclaimer applies to this non-confidential presentation prepared by Cryosite Limited ACN 090 919 476 (Cryosite) which is dated 7 May 2024 (Presentation). By accepting or receiving this Presentation, you acknowledge and agree to the terms set out below. Summary information T
Slide 3: Leadership Team
Leadership Team Experienced leadership team driving the business Experienced board of directors …with a talented management team Mark Kerr Andrew Kroger Andrew Kerr Scott Thomas John Hogg Jane Hao Chairman of the Board Non-Executive Director Non-Executive Director Non-Executive Director Chief Execut
Slide 4: Investment Highlights
Investment Highlights Leading Australian clinical trials logistics, storage and distribution company Leading clinical trial ▪ Over 23 years operating in the clinical trials and biological storage businesses ▪ Highly regulated, specialist storage and logistics solutions to the clinical trials and bio
Slide 5: Business Segments
Business Segments Cryosite operates through the following business segments cord blood Clinical Trial Logistics Biological Storage Cord Blood and Tissue Storage Independent supply chain expertise and third-party depot Specialist temperature-controlled storage provider specialising in clinical trials
Slide 6: Broad Scope of Clinical Trial Logistic Services
Broad Scope of Clinical Trial Logistic Services Cryosite offers a board range of services Characteristics of the services Inventory Control Reporting Reconciliation Web Portal Access Dry Shipping Clinical trial logistics Destruction Secure Witnessed Validated Supplier Certified Destruction Returns C
Slide 7: Market Overview: Poised for Growth
Market Overview: Poised for Growth 2028 Global Clinical Trials Market Forecast2,3 Global Clinical Trial market A$111bn CAGR 8.7% Global clinical trial supply o Australian R&D tax credit continues to make it attractive and logistics A$10.4b for overseas and domestic life science companies to conduct
Slide 8: Barriers to Entry
Barriers to Entry Significant barriers to entry creates a competitive advantage Licenses and Certifications GMP and GWP licenses are required to support the specialised needs of highly regulated, temperature-sensitive products Certification can take >2 years to achieve There is a significant lag in
Slide 9: Facility
Facility Purpose-built, modern facility licenced by the TGA 2,100m2 GMP and GWP-certified facility Secure site: > Back to base intrusion alarms > 24 hour / 7-day monitoring > Card access > Security Patrols 24-hour temperature monitoring Independent backup power by two generators IT secure systems wi
Slide 10: Clinical Trial Services Segment
Clinical Trial Services Segment 10
Slide 11: Clinical Trial Services
Clinical Trial Services Specialist temperature-controlled storage, logistics and distribution services Manage the entire clinical trial supply chain: Validated Inventory Management System and Quality Management System Receipt, retention & distribution of clinical supplies Labelling & secondary packa
Slide 12: Clinical Trial Services Specifications
Clinical Trial Services Specifications Cryosite currently manages 650+ clinical trials 650+ 9,300+ 99.97%2 shipments per annum, managing on-time dispatch rate 90% temperature current trials for shipments managed ~25% 20% All market share in market share of required licences held managing active clin
Slide 13: Clinical Trial Customers
Clinical Trial Customers High quality customer and end user base End Users of Direct Customers Customer Pharmaceuticals 11 of the top Universities Industry leading global 15 companies base CROs & CMOs Local and Research international Hospitals companies clients 13
Slide 14: Biological Storage Segment
Biological Storage Segment 14
Slide 15: Biological Storage Capabilities
Biological Storage Capabilities Specialist temperature-controlled storage Expertise, facilities, personnel and systems to provide a wide range of biological storage services for: Haematopoietic Cellular & Tissue Mesenchymal PK/PD Progenitor Cells Storage Stem Cells Samples Master & Working Human Pla
Slide 16: Biologics Specifications
Biologics Specifications Cryosite operates out of state-of-the-art 2,100m2 facility 2,100m2 33 20 GMP and GWP LN2 tanks -80°C freezers licensed site facility 7.5% 10 market share for -20°C freezers 4 biological storage in (including 2 being cold rooms Australia, and growing delivered) All S8 drugs r
Slide 17: Cord Blood and Tissue Storage Segment
Cord Blood and Tissue Storage Segment 17
Slide 18: Overview
Overview Experts in cord blood and tissue storage 1st 20+ Australian cord blood years’ experience service provider ~17,000 Therapeutics current customers accredited license (cord blood stored) 18
Slide 19: Cord Blood Use
Cord Blood Use One of the richest sources of stem cells, which have huge potential in the treatment of diseases • Umbilical cord blood is one of the richest sources of stem cells • Stem cells in cord blood have huge potential to treat chronic diseases such as cancer, diabetes, blood diseases and imm
Slide 20: Financials
Financials *eryosite 20
Slide 21: Capitalisation and Shareholders
Capitalisation and Shareholders Tightly held register with strong share price performance over the last ~4 years Capitalisation and Trading Shareholders2 Andrew Kroger Company ticker ASX:CTE (Director) Retail 41.1% Insiders Closing Price (6-May-2024) $0.85 Retail 34.4% 52 Week Trading Range $0.51 -
Slide 22: Historical Financials
Historical Financials Record financial results for FY23 Revenue (A$m) Clinical Trials and Biological Services Cord blood and tissue storage 6.2 6.4 5.8 5.9 5.7 5.1 1.1 • EBITDA annualised growth rate since FY2019 of 71.9% 4.9 1.2 4.9 1.2 1.2 1.2 4.0 4.0 4.2 1.3 • Organic growth is driving the top an
Slide 23: Cryosite
‘eryosite professional, dependable, compliant